D. Western Therapeutics Institute, Inc. (FRA:6DW)

Germany · Delayed Price · Currency is EUR

0.540

+0.020 (3.85%)

At close: Nov 28, 2025

4.85% (1Y)

Market Cap	30.27M
Revenue (ttm)	2.42M
Net Income (ttm)	-6.08M
Shares Out	n/a
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.540
Previous Close	0.520
Day's Range	0.540 - 0.540
52-Week Range	0.402 - 1.370
Beta	n/a
RSI	49.73
Earnings Date	Feb 13, 2026

About FRA:6DW

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to t... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 21

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 6DW

Full Company Profile

Financial Performance

In 2024, FRA:6DW's revenue was 471.00 million, an increase of 10.05% compared to the previous year's 428.00 million. Losses were -1.29 billion, 58.9% more than in 2023.

Financial numbers in JPY Financial Statements

News

There is no news available yet.